Information Provided By:
Fly News Breaks for January 29, 2018
MDRX
Jan 29, 2018 | 07:20 EDT
Cantor Fitzgerald analyst Steven Halper notes a FierceHealthcare.com article last week suggested that an ongoing Department of Justice investigation had affected the purchase price paid by the company for Practice Fusion. Given the terms of the acquisition, Allscripts will inherit any potential liability that arises from the investigation, Halper tells investors in a research note. He believes, however, that Allscripts management has a good understanding of the issue and is comfortable with Practice Fusion's legal position. Allscripts can absorb any "reasonable monetary settlement if that is the outcome," Halper adds. He reiterates an Overweight rating on the shares with a $17 price target.
News For MDRX From the Last 2 Days
There are no results for your query MDRX